Practical Clinical Consensus Guidelines for the Management of Cancer Associated Anemia in Low- and Middle-Income...

Area of Science:

• Oncology
• Hematology

Background:

• Cancer-associated anemia (CAA) is a prevalent complication affecting over 50% of cancer patients, significantly reducing overall survival (OS) and quality of life (QoL).
• Existing guidelines for CAA management do not adequately address the specific challenges faced in low- and middle-income countries (LMICs), such as impaired nutritional status and limited healthcare access.
• CAA is particularly common in gastrointestinal malignancies, head and neck cancers, and acute leukemias, with hemoglobin levels often declining further during cancer therapy.

Purpose of the Study:

• To develop evidence-based guidelines for managing cancer-associated anemia tailored to the unique context of LMICs.
• To provide recommendations for the evaluation and treatment of CAA, emphasizing accessible and affordable options.
• To highlight the importance of recognizing CAA as an independent prognostic factor impacting patient outcomes.

Main Methods:

• A consensus was reached among subject matter experts using a modified Delphi process, incorporating literature review and face-to-face discussions.
• Recommendations cover diagnostic evaluation, including complete blood count, red blood cell morphology, reticulocyte count, Coombs test, vitamin B12, folic acid, and comprehensive iron status monitoring.
• The preferred treatment modality identified is intravenous (IV) iron, specifically ferric carboxymaltose (FCM), administered as a single 1000 mg dose.

Main Results:

• A significant proportion of cancer patients (at least 50%) in LMICs require iron supplementation for CAA.
• Single-dose IV ferric carboxymaltose (FCM) at 1000 mg is demonstrated to be safe, effective, and well-tolerated, without the need for a test dose.
• Treatment with IV iron leads to rapid replenishment of iron stores, normalization of hemoglobin, improved QoL, and reduced risks associated with blood transfusions.

Conclusions:

• Cancer-associated anemia is a critical issue in LMICs that requires specific management strategies.
• Intravenous ferric carboxymaltose (FCM) is a highly effective and safe single-dose therapy for correcting CAA, improving patient QoL and OS.
• Increased awareness and timely diagnosis of CAA among healthcare professionals are crucial to prevent adverse outcomes and improve cancer care in resource-limited settings.